Walleye Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

Walleye Capital’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.2K	Sell	900 -5,400	-86%	-$83.5K	﹤0.01%	4426
2026 Q1	$87.6K	Sell	6,300 -25,300	-80%	-$356K	﹤0.01%	3718
2025 Q4	$382K	Buy	31,600 +9,400	+42%	+$128K	﹤0.01%	3127
2025 Q3	$302K	Buy	+22,200	New	+$209K	﹤0.01%	3000
2025 Q1	–	Sell	-23,000	Closed	-$86.9K	–	4204
2024 Q4	$86.9K	Buy	+23,000	New	+$108K	﹤0.01%	4192
2024 Q2	–	Sell	-7,300	Closed	-$20.7K	–	5547
2024 Q1	$20.7K	Sell	7,300 -12,600	-63%	-$165K	﹤0.01%	4915
2023 Q4	$293K	Sell	19,900 -5,200	-21%	-$79.7K	﹤0.01%	3384
2023 Q3	$460K	Buy	25,100 +11,500	+85%	+$243K	﹤0.01%	2883
2023 Q2	$293K	Buy	+13,600	New	+$367K	﹤0.01%	2826
2023 Q1	–	Sell	-2,900	Closed	-$107K	–	3896
2022 Q4	$107K	Buy	+2,900	New	+$103K	﹤0.01%	2334

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Walleye Capital's AMLX Position: Q2 2026 in Review

Walleye Capital increased its Amylyx Pharmaceuticals (AMLX) stake by 202% in Q2 2026, buying an estimated $1.93M and bringing the position to 186,588 shares worth $3.35M. The position accounts for 0.01% of the portfolio, ranked #1094.

Walleye Capital first reported a position in AMLX in Q1 2022 and has held it in 14 quarters since. The position peaked at $8.58M in Q4 2023. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Walleye Capital held 186,588 shares of Amylyx Pharmaceuticals worth $3.35M as of Q2 2026.
Walleye Capital bought 124,877 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $1.93M.
Amylyx Pharmaceuticals made up 0.01% of Walleye Capital's portfolio in Q2 2026, its #1094 holding.
Walleye Capital first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 14 quarters since.
Walleye Capital's Amylyx Pharmaceuticals position peaked at $8.58M in Q4 2023.
207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.